<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380601</url>
  </required_header>
  <id_info>
    <org_study_id>MRA225JP</org_study_id>
    <nct_id>NCT00380601</nct_id>
  </id_info>
  <brief_title>PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)</brief_title>
  <official_title>An Open-label, PhaseⅢ Study to Evaluate the Efficacy and Safety of MRA in Patients With RA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <brief_summary>
    <textblock>
      An open-label, PhaseⅢ study to evaluate the efficacy and safety of MRA in patients with RA
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of ACR 20％ improvement at the final visit</measure>
    <time_frame>throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of the frequency of ACR 20％, 50％ and 70％ improvement,time course of individual items within the ACR core set.</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of DAS28 to the final visit.</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of steroid sparing effect from first visit to final visit.</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRA(Tocilizumab)</intervention_name>
    <description>8mg/kg/4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as having RA, on the basis of the criteria stipulated by the American
             Conference on Rheumatism(ACR) in 1987

          -  Active RA despite at least one DMARDs or immunosuppressants or Infliximab or
             Etanercept.Active disease is defined as having at least 6 tender and 6 swollen joints
             among DAS28 (Modified Disease Activity Scores that include twenty eight joint counts)
             and ESR at least 30 mm/hr or CRP not less than 2.0mg/dL

          -  Active RA despite over 10mg adrenocortical steroids within 2 weeks before entry of
             this study

        Exclusion Criteria:

          -  Shown to have class-Ⅳ Steinbrocker's functional activity in an evaluation carried out
             within 4 weeks before administration of the study drug

          -  Treated with Infliximab within 3 months before and with Etanercept within 2 weeks
             before administration of the study drug

          -  Subjected to any of the following within 4 weeks before administration of the study
             drug:

               1. Surgical treatment (operations,etc.).

               2. Plasma exchange method
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuji Kimura</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical Co., Ltd. Research Dept.1</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chugoku region</name>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chukyo region</name>
      <address>
        <city>Chukyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido region</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokuriku region</name>
      <address>
        <city>Hokuriku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai region</name>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto region</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kousinetsu region</name>
      <address>
        <city>Kousinetsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu region</name>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sikoku region</name>
      <address>
        <city>Sikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku region</name>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2006</study_first_submitted>
  <study_first_submitted_qc>September 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2006</study_first_posted>
  <last_update_submitted>December 22, 2009</last_update_submitted>
  <last_update_submitted_qc>December 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical Co.,Ltd.</name_title>
    <organization>Chugai Pharmaceutical Co.,Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

